November 4-7, 2025 • Atlanta

Exhibitor Approval Policy and Form

Thank you for your interest in exhibiting at ObesityWeek® 2025! ObesityWeek® is home to the latest developments in evidence-based obesity science: cutting edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy.

Our exhibit review committee must approve all new exhibitors, as well as existing companies who wish to display a new product or service.

Vendors or products may be refused space if the committee feels they are not consistent with the mission of ObesityWeek and its member societies to safely treat or prevent obesity and weight-related bias.

Companies wishing to join ObesityWeek's list of approved exhibitors, please complete this form and email it to sgarcia@obesity.org.

Please include a product brochure/specific web page(s) and if you sell direct to attendees, your refund policy, to expedite the turn-around time for approval. This information will be sent to the review committee. You will be notified within two business days of your approval status.

Please note: Any company displaying products or services at ObesityWeek® 2025 that have not been previously approved by the review committee or found non-compliant with the general rules and regulations in place for the show may be dismissed from the exhibit area without refund or other appeal. The approval committee's decision is final.

Company Name: _____

Company Contact Email: _____

Company Website: _____

Company description, products and services:

_____

_____

_____

_____

Does your company sell the following? **An answer is required for each product type.**

Compounded Medications: ____ yes ____ no

TENS or other pain relief: ____ yes ____ no

Skin Care: ____ yes ____ no

Laser or UV products: ____ yes ____ no

FDA Status:_____Exempt ____Cleared (*Please note conditions on next page) ____N/A

Note: **Exhibitors selling products from their booth spaces** must post their refund policy in the booth in a manner both legible and clear and must explain the refund process clearly before taking payment for a product in the booth. Predatory pricing (significantly in excess of market rates for identical products) is not allowed. **Do not apply to exhibit at this conference if you are selling direct-to-consumer goods at prices substantially above market rates.** Attendee complaints regarding pricing and refunds will result in exhibitor's immediate removal from the exhibit hall.

We understand that our company is subject to final approval upon show opening and may be evicted from its rented space and further participation at ObesityWeek® Annual Meetings for violating the above policy.

Date:_____

Authorized Signature: _____

Title: _____

COMPOUNDED MEDICATIONS
The Obesity Society, Obesity Action Coalition and Obesity Medicine Association have issued a joint statement recommending that patients do not use compounded GLP-1 medications.

As a result, companies who provide compounded GLP-1 medications will not be granted exhibit privileges. To read the full statement, please click here: Do Not Use Compounded Alternatives to GLP-1 Medications.

FDA Market Clearance
No product, apparatus, instrument, device, or drug that is the subject of litigation pending before the US Food & Drug Administration (FDA) may be exhibited. All exhibitors for which FDA market clearance applies shall have documentation from the FDA on all products being displayed available at the booth. The documentation should state the model and regulatory class of those products that have been determined to be medical devices, as defined by the Federal Food, Drug, and Cosmetic Act, Section 201(h).

All devices that have not obtained FDA market clearance and are intended for use on humans or that are not commercially available in the US will be permitted for exhibit only when accompanied by the appropriate signs that indicate their status. The following are signs that should be displayed: (1) “This device is not for distribution in the United States”; (2) “Device is limited by federal law for investigational use”; (3) “Cleared for marketing when intended for only”; (4) “Pending FDA market clearance.” The signs must be easily visible and placed on or near the device itself and on any graphics depicting the device.

All products to be exhibited at ObesityWeek® conference must be identified on this form and must include FDA market clearance status, if applicable. This form will become part of the original application and contract.

NOTE: Prior to receiving the FDA market clearance of a 510(k) for a device, a manufacturer is limited in what promotional activities may be undertaken with regard to the device. Prior to the clearance of a 510(k), a manufacturer may advertise or display the device, but the device may not be sold, given away, held, or offered for sale, nor may orders be solicited, even upon the qualification that orders cannot be filled until the FDA acts on the 510(k), unless the device is limited to research or investigational use.

The failure to file a 510(k) is a misbranding violation [21 USC 352(o)]. Please contact the FDA Office of Compliance regarding your responsibilities under the Federal Food, Drug, and Cosmetic Act at 301/594-4692.